Streetbeat News

Revenues

BBW

Build-A-Bear Workshop's stock is trading lower following the release of mixed Q3 financial results and a reduction in their forecast for FY23.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:57 pm

LQR

LQR House Inc. (NASDAQ:LQR) reported a 300% increase in November revenue YoY, driven by a record-breaking Black Friday Cyber Monday weekend on its ecommerce platform CWSpirits.com. The company's total revenue for November reached $300,000, attributed to both marketing contracts and direct sales. CEO Sean Dollinger expressed excitement over the results and anticipates further success in the upcoming holiday season.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:53 pm

NTNX

Nutanix stock is up following the release of their Q1 financial results, which exceeded expectations. Additionally, the company has increased its revenue guidance for fiscal year 2024, signaling confidence in its future performance.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:42 pm

PSTG

Pure Storage reported Q3 revenue results that fell short of expectations and provided Q4 and FY24 revenue guidance that was below analyst estimates, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:41 pm

UAL

United Airlines Holdings announced a $2.6 billion terminal expansion at George Bush Intercontinental Airport in Houston. The project includes a state-of-the-art baggage system, a new club, and is expected to create thousands of jobs, increasing the airport's capacity by 40%.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:39 pm

CUEN

Cuentas, Inc. CEO Arik Maimon released a shareholder letter detailing the company's progress in acquisitions, real estate, and construction technology. CUEN is pivoting to real estate, fintech, and cybersecurity markets, with an imminent acquisition of WHEN Group, a move into the $215 billion global security market. The acquisition is pending Nasdaq and shareholder approval. CUEN is also expanding in mobile telecommunications, expecting $4 million in annual revenue from an initial order of 5,000 SIM cards. The company introduced 'Cuentas 360' with advanced security features and announced a partnership for mobile gaming and tokenized rewards in its fintech app. In real estate, CUEN partnered with RENCO on the Lakewood Village project and holds a 63% equity stake in a Tampa property project. Sales have increased to $1 million, a 861% quarter-over-quarter increase, with a 200% growth in cash and accounts receivable. A shareholder meeting is scheduled for December 20, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:32 pm

SPY

USA Personal Spending for October showed a 0.2% increase, aligning with the 0.2% estimate and showing a decrease from the 0.7% increase in the prior month.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:31 pm

ASO

Academy Sports (ASO) has updated its FY23 net sales forecast, narrowing the range from $6.175B-$6.365B to $6.110B-$6.170B, which is below the consensus estimate of $6.23B. The company also revised its adjusted EPS outlook, raising the lower end of the range from $6.95-$7.65 to $7.05-$7.20, compared to the estimate of $7.13.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:17 pm

BIAF

bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW) announced CMS' final payment determination for CyPath Lung, a noninvasive lung cancer test, effective January 2024. This facilitates reimbursement by Medicare and private payers, aiding commercialization. The AMA issued CPT code 0406U for CyPath Lung in June 2023, with CMS finalizing payment in November 2023. CyPath Lung uses flow cytometry and AI for early-stage lung cancer detection, showing high sensitivity and specificity in clinical trials.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:11 pm

GH

Guardant Health will present data at the San Antonio Breast Cancer Symposium showing the effectiveness of its liquid biopsy tests in biomarker identification, therapy selection, and detection of minimal residual disease (MRD). The studies highlight the Guardant Reveal™ test's ability to prognosticate distant cancer recurrence nearly eight months earlier than standard care methods.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 1:09 pm